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Summary 
Protein complexes are responsible for the bulk of activities within the cell, but how 
their behavior and abundance varies across tumors remains poorly understood. By 
combining proteomic profiles of breast tumors with a large-scale protein-protein 
interaction network, we have identified a set of 285 high-confidence protein 
complexes whose subunits have highly correlated protein abundance across tumor 
samples.  We used this set to identify complexes that are reproducibly under- or over-
expressed in specific breast cancer subtypes. We found that mutation or deletion of 
one subunit of a co-regulated complex was often associated with a collateral reduction 
in protein expression of additional complex members. This collateral loss 
phenomenon was typically evident from proteomic, but not transcriptomic, profiles 
suggesting post-transcriptional control. Mutation of the tumor suppressor E-cadherin 
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(CDH1) was associated with a collateral loss of members of the adherens junction 
complex, an effect we validated using an engineered model of E-cadherin loss. 
 
Introduction 
Multi-subunit protein complexes are responsible for the bulk of the functionality of 
the cell (Alberts, 1998; Hartwell et al., 1999). Despite their importance to cellular 
function, relatively little is known about how the functionality and expression of 
protein complexes is altered in different cancer subtypes or in individual cancer 
patients. Recent examples in breast cancer suggest that even ‘housekeeping’ 
complexes traditionally thought of as constitutively active and essential in all cell 
types, such as the ribosome and the spliceosome, may become differentially expressed 
or differentially essential in specific contexts (Hsu et al., 2015; Pozniak et al., 2016). 
Consequently there is a great need to characterize the altered behavior of protein 
complexes in cancer.  
 
Largely for technical and economic reasons, the large-scale molecular profiling of 
tumors performed over the past decade has focused on characterizing changes at the 
genomic and transcriptomic level. Transcriptomic measurements are often used as a 
proxy measurement for protein expression, but most genes display only a moderate 
correlation between their mRNA and protein expression levels (Liu et al., 2016; 
Vogel and Marcotte, 2012). Moreover, this correlation varies considerably between 
genes, with members of large protein complexes such as the ribosome and 
spliceosome reported to have significantly lower mRNA-protein correlation than 
average (Mertins et al., 2016; Zhang et al., 2016). Taken together, these observations 
suggest that efforts to understand altered protein complex functionality must rely on 
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more direct measurements of protein expression. Recently, advances in mass-
spectrometry have enabled the quantification of thousands of proteins across large 
numbers of samples (Mertins et al., 2016; Pozniak et al., 2016; Tyanova et al., 2016). 
These datasets permit, for the first time, a large-scale assessment of the behavior of 
protein complexes across different tumor samples and between different tumor types. 
Here, we develop an approach to identify co-regulated protein complexes from tumor 
proteomic profiles and characterize the expression of these protein complexes across 
77 breast tumor proteomes (Mertins et al., 2016).  
 
Results 
Similarity of co-expression profiles is highly predictive of protein complex 
membership 
We first wished to assess whether known protein complexes are coherently regulated 
across tumor proteomes. Using the CORUM manually curated set of human protein 
complexes (Ruepp et al., 2010) and 77 protein expression profiles from the Cancer 
Genome Atlas (TCGA) breast cancer proteomics project (Mertins et al., 2016) we 
assessed the relationship between the similarity of protein-expression profiles and the 
likelihood of two proteins belonging to the same protein complex (Figure S1A). In 
comparison to the correlation observed using mRNA expression profiles, protein 
expression profiles were more predictive of co-complex membership (Figure S1A). 
This observation is consistent with recent work that found, using tumor profiles, that 
protein co-expression was more predictive of general functional similarity than 
mRNA co-expression (Wang et al., 2017). We assessed whether reducing molecular 
heterogeneity, by calculating protein co-expression on samples from a single breast 
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cancer subtype, would improve our ability to predict protein complex membership 
from protein expression and found no obvious improvement (Figure S1B, S1C). 
 
Although co-expression calculated over the same number of samples suggested a 
significant advantage of proteomic profiles over mRNA profiles, the number of 
existing tumors with mRNA profiles far exceeds the number with proteomic profiles. 
We found that even with all TCGA breast tumour samples included (~14 times as 
many mRNA profiles as proteomic profiles) the proteomic profiles still outperformed 
mRNA in predicting co-complex membership (Figure S1A). This suggested that post-
transcriptional processes such as translation and protein turnover may significantly 
contribute to maintaining the stoichiometry of protein complexes. Consistent with this 
we found that the median Pearson’s correlation between mRNA and protein 
expression for genes annotated in CORUM complexes is significantly lower than that 
for all other genes (0.36 for genes in complexes vs 0.4 for all other genes, Mann 
Whitney p < 1.5x10-6) suggesting increased post-transcriptional control of protein 
complex subunits.  
 
While in general the expression of different subunits within the same CORUM 
complex was highly correlated, this was not the case for all complexes examined, 
suggesting that not all complexes are coherently regulated to a similar degree in breast 
cancer (Figure S1D). Moreover, visual exploration of the expression data suggested 
that there were highly-correlated groups of proteins corresponding to known 
complexes that were absent from the CORUM curated set. With these issues in mind, 
for further analysis we elected to use a data-driven approach to identify protein 
complexes coherently regulated in breast cancer (Figure 1A). 
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A compendium of protein complexes co-regulated in breast tumors 
We hypothesized that by integrating large-scale protein-protein interaction networks 
with proteomic profiling we could identify protein complexes coherently regulated in 
breast tumors. We first constructed a large network of protein-protein interactions by 
integrating literature curated interaction databases (Chatr-Aryamontri et al., 2016; Das 
and Yu, 2012) with recently generated large scale high-throughput protein interaction 
maps (Havugimana et al., 2012; Hein et al., 2015; Huttlin et al., 2015; Wan et al., 
2015)(Figure 1A). As expected we found that integrating this protein interaction 
network with co-expression improved our ability to predict co-complex membership 
(Figure S1E, STAR Methods). To identify sets of genes that are densely connected on 
this network and display highly correlated expression profiles across multiple tumor 
samples we developed a constrained clustering approach that integrated the protein-
protein interaction network with proteomic expression profiles from 77 breast tumors 
(Mertins et al., 2016) (Figure 1A, STAR Methods). Using this approach we identified 
a high-confidence set of 285 complexes encompassing 1,116 distinct proteins (Figure 
S1, Table S1). We refer to this set of complexes throughout as BrCa-Core 1-285. The 
identified complexes range in size from 2 subunits to 43 subunits (mean size = 3.9) 
with the largest complex corresponding to the cytosolic ribosome (BrCa-Core 1). Just 
under half of the BrCa-Core complexes (n=138) significantly overlap with literature 
curated complexes annotated in CORUM (adjusted p < 0.05), including the COP9 
signalosome (Figure 1B, BrCa-Core 17) (Seeger et al., 1998) and the conserved 
oligomeric Golgi (COG) complex (Figure 1C, BrCa-Core 14) (Ungar et al., 2002). 
Some of the BrCa-Core complexes encapsulated protein complexes already annotated 
in CORUM along with additional subunits – for example BrCa-Core 47 included the 
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CORUM annotated origin-recognition 2-5 complex (ORC 2-5) (Dhar and Dutta, 
2000) with the addition of LWRD1 which interacts with the ORC complex and 
stabilizes binding of the complex to chromatin (Shen et al., 2010) (Figure 1D). 
Complexes identified in BrCa-Core but absent from the CORUM human complex set 
include the COPI-vesicle coat complex (Figure 1E, BrCa-Core 25), a variant of the 
endosome-associated recycling protein (EARP) complex that includes all four EARP 
subunits along with the more recently identified EARP interactor TSSC1 (Gershlick 
et al., 2016; Schindler et al., 2015)(Figure 1F, BrCa-Core 48), and a complex 
containing the majority of subunits of the newly identified ‘Commander’ 
(COMMD/CCDC22) complex (Figure 1G, BrCa-Core 26) (Starokadomskyy et al., 
2013) recently shown to be highly conserved across metazoans (Wan et al., 2015).  
 
The majority of BrCa-Core complexes have significant overlap with specific Gene 
Ontology Cellular Component and Biological Process terms, suggesting common 
localization and functionality respectively (208 complexes enriched in GO-CC terms, 
235 enriched in GO-BP terms, both at adjusted p < 0.05) (Table S1). Like known 
protein complexes, pairs of proteins assigned to the same BrCa-Core complex were 
significantly more likely than random protein pairs to be frequently mentioned 
together in the literature (Odds-Ratio 175, p < 1x10-16, Fisher’s exact test) and to 
display similar patterns of conservation across species (Odds-Ratio 277, p < 1x10-16, 
Fisher’s exact test).  
 
As our method exploited the correlation between protein expression profiles to 
identify complexes, we expected the average correlation across the TCGA proteomes 
within the BrCa-Core complexes to be high. This was indeed the case - the observed 
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correlation (0.63) was higher than the average of pairs in our integrated protein 
interaction network (PPI pairs, 0.12) or pairs within CORUM complexes (0.20). To 
rule out the possibility that we were merely overfitting our results to a single 
proteomics dataset we assessed whether the same higher correlation could be 
observed in two additional breast tumor proteomic datasets (Pozniak et al., 2016; 
Tyanova et al., 2016). In both Pozniak et al (BrCa-Core = 0.28; CORUM = 0.14; PPI 
pairs = 0.10) and Tyanova et al (BrCa-Core = 0.32; CORUM = 0.19; PPI pairs = 
0.12), we found higher average correlation for BrCa-Core pairs. 
 
The tendency of pairs of proteins within the same complex to display similar 
phenotypes when inhibited has been well established in the literature (Sharan et al., 
2007; Wang and Marcotte, 2010). To assess whether the BrCa-Core complexes also 
displayed a similar tendency, we analyzed the results of a recently published large-
scale shRNA screen in 77 breast tumor cell lines (Marcotte et al., 2016). We expected 
that shRNAs targeting members of the same complex would display correlated 
essentiality profiles (i.e. would inhibit tumor cell lines in a similar fashion) and we 
found that this is indeed the case (BrCa-Core = 0.24; CORUM = 0.07; PPI pairs = 
0.06).  
 
The BrCa-Core complexes contain complete or partial coverage of 538 CORUM 
complexes (average percent of CORUM complex members included in the 
corresponding BrCa-Core complex is 57%) corresponding to 39% of the CORUM 
complexes represented in the proteomic dataset (538/1380). We note that this is larger 
than the number of BrCa-Core complexes that significantly overlap with CORUM 
complexes (138) due to the heavily overlapping nature of CORUM complexes. In 
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CORUM the average protein belongs to 3 distinct complexes, while by design in 
BrCa-Core each protein was assigned to a single complex based on highly correlated 
expression with other members. The subset of CORUM co-complex pairs we identify 
in BrCa-Core have higher average protein co-expression (average correlation 0.65) 
than those not identified in BrCa-Core (average correlation 0.16). One explanation for 
this is that we have preferentially identified complex cores or modules (Gavin et al., 
2006). Many protein complexes exist in multiple isoforms, with the exact composition 
varying across cell types and conditions. Previous work in yeast has suggested that 
the subunits of protein complexes can be divided into two groups - cores (proteins 
found in the majority of complex isoforms) and attachments (proteins found in a small 
number of isoforms)(Gavin et al., 2006). Some pairs of attachment proteins are often 
found together in multiple complexes, and these have been referred to as 
‘modules’(Gavin et al., 2006). Consistent with BrCa-Core preferentially identifying 
‘cores’ or ‘modules’ we found that pairs of proteins annotated together in two or more 
CORUM complexes were more likely to be identified together in a BrCa-Core 
complex (Odds-Ratio=1.9, p < 1x10-16, Fisher’s exact test) as were pairs always found 
in the same CORUM complex (Odds-Ratio=6.6, p < 1x10-16, Fisher’s exact test). 
 
Differential expression of protein complexes in breast cancer subtypes 
At the molecular level breast cancer is a very heterogeneous disease, with each tumor 
displaying a unique genetic and epigenetic profile. Despite this heterogeneity, 
molecular biomarkers can be used to classify tumors with similar molecular profiles 
into subtypes that display different survival outcomes and different responses to 
targeted therapies (Onitilo et al., 2009; Perou et al., 2000; Sorlie et al., 2001). The 
biomarkers used most commonly in the clinic are the estrogen receptor (ER), 
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progesterone receptor (PR) and human epidermal growth factor receptor 2 
(ERBB2/HER2), often measured using immunohistochemistry (IHC) (Onitilo et al., 
2009). To better understand how breast cancer subtypes might influence protein 
complexes (and vice-versa) we assessed the relationship between BrCa-Core protein 
complex expression and IHC-defined subtypes.  To enable the identification of 
reproducible associations between subtypes and protein complex abundance we 
focused on those subtypes with reasonable representation in both the TCGA dataset 
and the dataset of Tyanova et al (Tyanova et al., 2016) - HER2+ (ER-/PR-/HER2+), 
ER+ (ER+/PR+/HER2-) and triple negative (ER-/PR-/HER2-). 
 
Using the TCGA dataset and the BrCa-Core complexes, we discovered 80 
associations between subtype and complex abundance at a FDR of 10% (Table S2, 
Figure 2). At the same FDR threshold we found 7 associations using the CORUM 
complex set, highlighting the advantage of using co-regulated BrCa-Core complexes 
for this analysis. Due to differences in coverage of protein complex subunits, not all 
of the 80 associations could be tested in the Tyanova et al dataset. Of the 58 
associations that could be tested 27 were observed at the same FDR of 10% (Table 
S2). In general the effect sizes and directions across the two datasets were highly 
correlated (Spearman’s r = 0.68, p < 1x10-8) suggesting that with larger sample sizes 
additional associations between subtype and complex abundance could be replicated. 
Examples of replicated differentially expressed complexes are presented in Figure 2 
and Figure S2. Triple-negative breast tumors were associated with increased 
expression of a number of complexes involved in DNA replication including the 
replication factor C complex (BrCa-Core 21) and the MCM complex (BrCa-Core 28) 
(Figure 2A, Figure S2). Different members of the MCM complex (MCM2 and 
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MCM4) have previously been identified as markers of proliferation, associated with 
poorer survival outcomes in breast cancer and shown to have higher expression in ER 
negative breast tumors (Joshi et al., 2015; Kwok et al., 2015). ER+ tumors were 
associated with decreased expression of two complexes involved in antigen 
processing (BrCa-Core 59 and 193) consistent with data suggesting that expression of 
antigen presentation human leukocyte antigen (HLA) molecules is lower in the ER+ 
subtype (Chung et al., 2017; Lee et al., 2016). HER2+ tumors were associated with 
increased expression of two complexes involved in Golgi transport associated vesicle 
coating (BrCa-Core 25 and 42). It is not immediately obvious why HER2 
amplification would be associated with an increased expression of complexes 
involved in vesicle transport, but the association is evident across both patient cohorts 
(Figure 2B, Figure S2, Table S2).  
 
The impact of subunit loss on protein complex expression 
An implication of highly correlated protein expression within a protein complex is 
that loss of protein expression of one subunit might frequently be associated with 
reduced protein expression of other co-regulated complex subunits (Figure 3A). Such 
a reduction in expression may occur through reduced transcription, reduced 
translation, or an increase in protein degradation. Consequently genetic events that 
reduce protein expression of one subunit, such as mutation or deletion, may be 
associated with a collateral reduction (in trans) of protein expression of other subunits 
or indeed the entire complex (Figure 3A). To test whether this is the case we first 
focused on genes subject to homozygous deletion or mutation, reasoning that they 
might cause the most profound effects on protein expression. We identified five genes 
that are members of BrCa-Core complexes whose mutation or homozygous deletion is 
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associated with a nominally significant (p < 0.05, Mann Whitney U test) reduction in 
expression of their encoded proteins (CDH1 (E-cadherin), PBRM1, CYFIP2, GLUD1, 
EXOC2). We then asked whether mutation or deletion of these genes was also 
associated with overall reduction in protein expression of the complex that they 
belong to. In all five cases we found that loss of one subunit was associated with a 
reduction in the protein expression of additional complex subunits. For instance 
homozygous deletion or mutation of EXOC2 was associated with decreased 
proteomic abundance of EXOC2 and an overall reduction in the protein expression of 
multiple members of the exocyst complex (BrCa-Core 27) (Matern et al., 2001) to 
which it belongs (Figure 3B). While loss of EXOC2 was also associated with a 
reduction of EXOC2 mRNA expression, no reduction was observed for other protein 
complex subunits at the mRNA level (Figure S3A) suggesting that the reduction in 
protein expression levels is caused by post-transcriptional mechanisms. Furthermore, 
the correlation between complex subunits was higher at the protein than mRNA level 
(Figure S3B) suggesting these post-transcriptional mechanisms may contribute to the 
coherent protein expression of the complex.  
 
While mutations or homozygous deletions of complex subunits are relatively rare, 
hemizygous (single copy) deletions in tumors are frequent and the majority of BrCa-
Core member genes were hemizygously deleted in three or more tumor samples 
(1053/1116 genes). We identified 308 BrCa-Core complex members whose 
hemizygous deletion was associated with a reduction in the expression of their 
encoded protein (Mann Whitney p < 0.05, Table S3). The majority of these (94%, 290 
genes) were also associated with a reduction in mRNA expression of their encoded 
genes at the same significance threshold. We then tested whether these 308 genes 
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were associated with an overall reduction in the protein expression of their associated 
complex (see STAR Methods) and found that 102 genes were at an FDR of 10% 
(Table S3). To ensure this reduction was not merely due to co-deletion of complex 
members on the same chromosome, we excluded gene pairs located on the same 
chromosome for this analysis. Of the 102 associations, only 6 were associated with a 
reduction in mRNA expression of their associated complex at an FDR of 10% (Table 
S3). This suggests that although hemizygous deletion frequently causes a reduction in 
both mRNA and protein levels of the encoded protein, the impact upon other 
members of the complex is typically only observed at the protein level. A striking 
example involves the COP9 signalosome (BrCa-Core 17, Fig. S4A) - hemizygous loss 
of COPS3 is associated with a reduction in the protein expression of all subunits (Fig. 
S4B), but only the mRNA expression of COPS3 itself (Fig. S4C). As with the exocyst 
complex, COP9 subunits were more highly correlated at the protein (Fig. S4D) than 
mRNA level (Fig. S4E). 
 
E-cadherin loss causes reduced expression of adherens junction complex 
members 
Loss of E-cadherin is a major driver event in breast cancer, with its coding gene 
CDH1 mutated in ~11% of all breast tumors and over 50% of invasive lobular breast 
tumors (Berx et al., 1995; Ciriello et al., 2015; Michaut et al., 2016). Our analysis 
identified that mutation of CDH1 was associated with a decreased abundance of both 
the E-cadherin protein and additional members of an adherens junction complex to 
which it was assigned in BrCa-Core (BrCa-Core 30) (Figure 3C, Figure S3C). All 
proteins in this complex have highly correlated protein expression with E-cadherin 
(average Pearson’s correlation 0.65, Figure S3D) and four of the complex subunits 
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have a significant (Mann Whitney p < 0.05) decrease in expression in CDH1 mutant 
samples (Figure 3C). In contrast, the average mRNA correlation of all subunits with 
CDH1 was low (Pearson’s correlation 0.08) with one subunit (CTNNB1) displaying 
weakly negative correlation with E-cadherin (Figure S3D). None of the subunits other 
than E-cadherin itself display a significant relationship between CDH1 mutation 
status and mRNA expression (all Mann Whitney p > 0.05, Figure S3C). Three of the 
proteins in this complex (E-cadherin / CTNNA1 / CTNNB1) have also been measured 
in a larger sample size using the RPPA method permitting us to assess the association 
between CDH1 mutation and protein abundance measured using an orthogonal 
approach. Using the RPPA data we again found that CDH1 mutation was associated 
with a significant reduction in abundance of all three proteins (Figure 4A) but only 
the mRNA of CDH1 itself (Figure 4A).  
 
A limitation of our analysis of tumor proteomes is that it identifies correlative rather 
than causal associations – it demonstrates that mutation of CDH1 is associated with 
reduced expression of other E-cadherin associated subunits, but it does not 
demonstrate a causal effect. It is of course possible that some additional factor causes 
reduction in expression of the entire adherens junction complex rather than the 
mutation of a single subunit such as CDH1. To establish causality we used mass 
spectrometry to measure differential protein expression in a pair of isogenic breast 
cancer cell lines (MCF7) with CRISPR-Cas9 engineered CDH1 loss (STAR 
Methods). We recently generated a series of CDH1 mutant clones in the MCF7 cell 
line (Bajrami et al, personal communication) and selected one for further study which 
exhibited loss of E-cadherin protein expression (Figure S5, STAR Methods). We 
performed label-free protein quantification of whole protein lysates in parental 
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(MCF7 E-cadherin wild type) and E-cadherin defective daughter cells, resulting in the 
quantification of ~5,100 proteins (Table S4, STAR Methods). We found 91 proteins 
with significantly lower protein abundance in the E-cadherin defective model (p < 
0.005, FDR = ~8%) including five of the six adherens junction complex subunits (E-
cadherin, CTNNA1, CTNNB1, CTNND1, JUP) (Figure 4B), suggesting that CDH1 
mutation plays a causative role in the reduction of their protein abundance. In contrast 
to what we observe in the tumor proteomes, in the MCF7 E-cadherin null model we 
observed an increase in the expression of CDH3 (P-cadherin) (Figure 4B), perhaps an 
example of ‘cadherin switching’ specific to this model (Cavallaro et al., 2002; 
Wheelock et al., 2008). The decreased abundance of five of the six BrCa-Core 
adherens junction complex members in the MCF7 model was a significant enrichment 
over random expectation (Odds Ratio=280, p=10-8 Fishers Exact Test).  To test 
whether our approach missed additional collateral loss events associated with CDH1 
mutation we assembled a list of 95 E-cadherin protein-protein interaction partners 
from CORUM (18 co-complexed subunits), BioGRID (89 protein-protein interaction 
partners) and HINT (15 co-complex interaction partners). Aside from the five 
members of the adherens junction complex in BrCa-Core, none of the known E-
cadherin interaction partners displayed a significant reduction in protein abundance in 
the E-cadherin defective model. This suggested that our data-driven approach 
effectively identified the specific subunits of the adherens-junction complex whose 
expression is reduced by CDH1 mutation in breast cancer.  
 
Discussion 
We found that in general, correlation between protein expression profiles predicts co-
complex membership better than correlation between mRNA expression profiles. One 
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factor that contributes to this improved correlation is the collateral loss phenomenon 
we observe - when one subunit of a complex is lost via deletion or mutation, a 
collateral loss in the protein expression of additional complex members is observed. 
This collateral loss is typically not observed at the mRNA level, and consequently 
complexes that experience collateral loss display higher correlation at the protein than 
mRNA level. There are likely many other factors that contribute to maintaining the 
coherent expression of protein complexes across tumors, including dosage 
compensation of copy number amplified genes (Geiger et al., 2010; Stingele et al., 
2012).  
 
We have not addressed here the mechanisms responsible for the collateral loss 
phenomenon, although the observation that the reduction in protein expression levels 
is not evident at the mRNA level suggests posttranscriptional mechanisms must be 
responsible. Perhaps the simplest explanation is that loss of one subunit prevents a 
complex from assembling, and consequently there is an increase in the proteasomal 
degradation of unbound subunits. Our analysis of hemizygous deletions suggests that 
complete loss of protein expression is not necessary for the collateral loss 
phenomenon. Similarly we note that work in mice suggests that regulatory mutations 
that impact the mRNA expression of individual protein complex subunits may also 
cause a collateral loss in the expression of their interaction partners (Chick et al., 
2016). 
 
We note we did not always observe perfect agreement between the genotype calls in 
tumors and protein expression – in some instances copy number analysis suggested a 
homozygous deletion but substantial protein expression was still observed. This could 
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reflect errors in calling the deletions, limitations of mass-spectrometry protein 
identification, or simply heterogeneity between the portion of the tumor sample 
assessed for proteomic profiling and the portion assessed for genotypic profiling. 
 
We have exclusively focused on the behavior of coherently expressed protein 
complexes across breast tumor samples. This approach has a number of advantages - 
in particular it allows us to see how different complexes behave as a single unit within 
molecularly defined groups of tumors. A disadvantage of this approach is that we 
cannot identify when different variants / isoforms of a protein complex become more 
or less abundant in specific conditions. We have overlooked such events here, but 
recent work in cancer cell lines and mouse fibroblasts suggest that they may be 
relatively common and merit further investigation (Ori et al., 2016). 
 
We expect that the BrCa-Core complexes will be useful for the analysis of additional 
proteomic and functional datasets and make the full list of complexes available in 
Table S1. We also anticipate that the complex identification approach described here 
will be useful for the analysis of other large-scale proteomic datasets, such as those 
from other tumor or cell line profiling projects and we make our code available to 
facilitate such efforts. 
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Figure Legends  
Figure 1. BrCa-Core complex discovery. A) Schematic - an integrated protein-
protein interaction network is combined with tumor proteomic profiles to identify sets 
of densely connected proteins that display correlated expression profiles across tumor 
proteomes. By comparing the results to those derived from randomly relabeled 
protein interaction networks we can estimate the false-discovery rate (FDR). The 
BrCa-Core set contains 285 complexes at an estimated FDR of 10%. B) BrCa-Core 
17 - the COP9 signalosome. The heatmap in the right shows protein expression of all 
subunits across 77 breast tumor proteomes. These have been sorted based on the mean 
abundance of all subunits C) BrCa-Core 14 - the conserved oligomeric golgi (COG) 
complex. D) BrCa-Core 47 - contains ORC2-5 complex found in CORUM with the 
addition of LRWD1 E) BrCa-Core 25 - the COPI complex F) BrCa-Core 48 - the 
EARP complex with the recently identified EARP interactor TSSC1 G) BrCa-Core 26 
- the Commander complex 
 
Figure 2. Subtype specific complex expression. A) Heatmap displaying protein 
expression levels of specific BrCa-Core complexes. Tumor samples are grouped 
according to subtype (using IHC markers), indicated on top of the heatmap. Genes are 
grouped into specific complexes indicated on the right of the heatmap. Shown are the 
expression levels taken from Tyanova et al (used for validation). These expression 
levels have been normalized such that the maximum expression level is 1 and 
minimum is 0. Heatmap for the discovery dataset (Mertens et al) is shown in Figure 
S2A. Complexes differentially expressed in specific subtypes are highlighted with 
boxes colored to match the subtype they are differentially expressed in. B) Boxplots 
displaying the subtype specific protein expression levels of selected subunits of the 
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COPI complex (BrCa-Core 25) in the Tyanova et al dataset (top) and TCGA dataset 
(bottom). These box plots show median and interquartile range and are colored 
according to sample subtype (matching Figure 2A).  
 
Figure 3. Subunit loss is associated with a reduction in protein complex 
expression. A) Model displaying potential series of events – mutation or deletion of 
one subunit is associated with reduced protein abundance of that subunit, and 
potentially a reduction in expression of the entire complex. B) Mutation or deletion of 
EXOC2 is associated with a reduction in protein abundance of the exocyst complex 
(BrCa-Core 27). Boxplots display the protein abundance of different subunits 
partitioned according to EXOC2 status. Each box plot shows the median and 
interquartile range.  Genes marked with a star indicate those whose proteomic 
abundance is significantly lower (one-sided Mann Whitney test, p<0.05) in samples 
with EXOC2 mutation/deletion.  C) CDH1 mutation is associated with a reduction in 
protein expression of an adherens-junction complex (BrCa-Core 30). Legend as for B. 
 
Figure 4. E-cadherin loss is associated with reduced expression of an adherens 
junction complex. A) In tumor samples CDH1 mutation is associated with a decrease 
in mRNA and protein expression of CDH1, but only of protein expression for 
CTNNA1 and CTNNB1. All expression and RPPA measurements are Z-scores. Box 
plots show median and interquartile range. P-values calculated using a Mann Whitney 
test. mRNA measurements for all three genes were available for 992 tumors, RPPA 
data for CDH1 and CTNNB1 were available for 760 tumors, while RPPA data for 
CTNNA1 was available for only 64 tumors. B) Protein expression measured in a pair 
of isogenic MCF7 cell lines that differ by CDH1 status. Shown are the log2 Label 
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Free Quantification intensities. P-values are calculated using a two-sided 
heteroscedastic t-test. 
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STAR Methods 
CONTACT FOR REAGENT AND RESOURCE SHARING  
Further information and requests for resources and reagents should be directed to and 
will be fulfilled by the Lead Contact, Colm J. Ryan (colm.ryan@ucd.ie)  
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
 
MCF7 cell line are derived from a female breast tumour and were grown in DMEM 
(Gibco) supplemented with 10% fetal bovine serum (Gibco) and 1% L-glutamine 
(Gibco).  
 
METHOD DETAILS 
 
MCF7 E-cadherin Defective Clone Selection 
The CDH1 gene in MCF7 cells was CRISPR-Cas9 mutagenised using the Edit-R-
CRISPR-CAS9-gene engineering kit (GE Dharmacon) according to the supplier’s 
instructions. A crRNA sequence targeting exon 7 of CDH1 was used. Briefly, MCF7 
cells were transfected in 24 well plates with tracerRNA, crRNA and Cas9 plasmid. 72 
hours after transfection, cells were plated in 15 cm dishes and continuously cultured 
until colonies formed. Colonies were recovered and profiled using PCR and Sanger 
sequencing to determine the presence of CDH1 gene mutations. Loss of E-cadherin 
expression in the selected clone was confirmed using Western blotting (Figure S5). 
This cell line is available upon request to the Lead Contact. 
 
Total lysate preparation for Mass spectrometry 
Cells were plated in 100 mm dishes. Once confluent, media was discarded and cells 
were washed in PBS. Cells were lysed in a lysis buffer containing 2% SDS (Fisher 
Scientific), 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM MgCl2, (Sigma Aldrich) 
supplemented with protease inhibitor tablets (Roche) and phosphatase inhibitors (2 
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mM sodium orthovanadate, 10 mM sodium fluoride and 10 mM -
glycerophosphate) (Sigma-Aldrich). Lysates were subjected to sonication (Syclon 
ultrasonic cell disrupter), boiling (95°C, 5 min) and placed on ice for 10-15 min prior 
to centrifugation (14000 rcf, 10 min). The supernatant was transferred to fresh 
eppendorfs and samples were subsequently placed on ice for a further 10-15 min to 
allow the SDS to precipitate and re-centrifuged. Supernatant was transferred to fresh 
eppendorfs and protein concentration was measured using the Pierce BCA protein 
assay kit as per manufacturers instruction (Thermo Scientific), using a SpectraMax 
M3 (Molecular Devices). Once quantified, DL-dithiothreitol (DTT) was added to the 
lysates at a final concentration of 0.1 M DTT. Subsequently, lysates were boiled 
(95°C, 5 min). Detergent was removed from the lysates prior to MS analysis using the 
Filter Aided Sample Preparation (FASP) procedure incorporating Vivacon spin 
ultracentrifugation units with a molecular weight cutoff of 30 kDa 
(Sartorius)(Wisniewski et al., 2009). Briefly, 200 l of urea buffer (Fisher Scientific) 
UA buffer (8 M urea in 0.1 M Tris-HCl pH 8.9) was added to 100 g of cell lysate. 
Samples were added to the filter unit and centrifuged at 14000 rcf for 15 min. An 
additional 200 l of UA buffer was added to the filter unit and re-centrifuged. 
Iodoacetamide (100 l, 0.05 M prepared in UA buffer) was added to the filter units, 
incubated for 1 min on a thermomixer at 600 rpm and subsequently incubated in 
darkness for 20 min. Following the incubation period, filter units were centrifuged 
and washed twice with 100 l of UA buffer followed by 2 washes with 100 l of 
ABC solution (0.05 M NH4HC03). After the final wash step, filter units were 
transferred to a new collection tube and a multi-step digestion method was employed 
as described by Wisniewski and Mann (Wisniewski and Mann, 2012). In the first 
instance, proteins were digested in a wet chamber overnight at 37°C using a solution 
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containing Lys-C (Lysl Endopeptidase, Wako) and ABC buffer (1:50, enzyme to 
protein ratio). The following day, liberated peptides were collected by centrifugation 
and subsequent wash cycles with ABC buffer. Meanwhile, remaining proteins on the 
filter unit were digested using a solution containing Sequencing Grade Modified 
Trypsin (Promega) and ABC buffer in a wet chamber at 37°C for a minimum of 4 hr. 
Once again liberated peptides were collected by centrifugation and subsequent wash 
cycles with ABC buffer. The concentration of the Lys-C digests and Trypsin digests 
were measured using a NanoDrop 2000. In total, 10 g of each digest was loaded 
onto activated handmade C18 StageTips as described previously(Rappsilber et al., 
2003). StageTips were desalted with two 1% TFA wash cycles and bound peptides 
were eluted with 2 X 25 l of 50% ACN/0.1% TFA. Final eluates were concentrated 
in the speed-vacuum centrifuge (Centri-Vap concentrator, Labconco to a final volume 
of ~5 l. Samples were then resuspended by adding 0.1% acetic acid, to a final 
volume of 15 l and analyzed by mass spectrometry. 
 
Mass Spectrometry 
Mass spectrometry analysis was performed on a Q-Exactive mass spectrometer 
(Thermo Scientific), connected to a Dionex Ultimate 3000 (RSLCnano) 
chromatography system (Thermo Scientific) incorporating an autosampler. Five 
microliters of Lys-C/tryptic peptides was loaded onto a fused silica emitter (75m 
ID, pulled using a laser puller (Sutter Instruments P2000)), packed with 1.8 120Å 
UChrom C18 packing material (NanoLCMS Solutions) and separated using an 
increasing acetonitrile gradient of 2 – 35%, with a 180 min reverse phase gradient at a 
flow rate of 250 nl/min. The instrument was operating in positive ion mode and with a 
capillary temperature of 320°C, coupled to a potential of 2300V applied to the 
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column. Scan parameters for MS1 were as follows: Resolution 70,000, AGC 3e6, MIT 
60ms while scan parameters for MS2 were: Resolution 17,500, AGC 5e4, MIT 250ms, 
NCE 27.0, Isolation window 1.6m/z. The exclusion list parameters contained no 
entries and charge exclusion was set to un-assigned and singly charged. Both MS1 
and MS2 were recorded as profile data. Data were acquired in automatic data-
dependent switching mode, with a high-resolution MS scan (300-1600 m/z) selecting 
the 12 most intense ions prior to tandem MS (MS/MS) analysis. Each biological 
sample (n=3) was run in technical duplicate. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
Protein ID matching 
Identifiers in all protein-protein interaction networks, protein expression datasets, and 
validation sets were converted to ENTREZ gene IDs. In cases where a particular gene 
or protein could not be matched to an ENTREZ gene ID it was discarded from further 
analyses. 
 
Protein Expression Data Processing 
For the primary analysis we used the breast tumor proteomics dataset from the TCGA 
CPTAC project (Mertins et al., 2016). Only samples that passed the authors’ quality 
control (77 samples, 3 replicates, 3 controls) were used in our analysis. For validation 
we used two additional datasets – Tyanova et al (Tyanova et al., 2016) containing 40 
tumor proteomes from diverse breast cancer subtypes, and Pozniak et al (Pozniak et 
al., 2016) containing 66 proteomes from primary luminal-type breast tumors or 
metastases. The dataset of Tyanova et al contains SILAC ratios which we converted 
using a log2 transformation prior to calculating correlations. For all proteomics 
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datasets proteins absent in more than 40% of samples were discarded. As the average 
Pearson’s correlation between protein isoforms of the same gene was extremely high 
(0.95 in Mertins et al) multiple proteins mapping to the same gene were averaged into 
a single gene-level score. The resulting datasets contained profiles for 9,833 proteins 
(Mertins et al., 2016), 5,248 proteins (Tyanova et al., 2016) and 4,361 proteins 
(Pozniak et al., 2016).  
 
Protein Interaction Network Assembly 
We assembled an integrated protein interaction network from multiple sources. From 
the HINT database (Das and Yu, 2012) we included all co-complex interactions that 
were reported in at least two publications. From the BioGRID database (Chatr-
Aryamontri et al., 2016) we included all protein-protein interactions in the multi-
validated interactome – a network of interactions that were either observed in two 
experimental systems or in two separate publications. We augmented this set of high-
confidence interactions with the result of four recent large-scale protein interactome 
mapping efforts (Havugimana et al., 2012; Hein et al., 2015; Huttlin et al., 2015; Wan 
et al., 2015). The resulting integrated network contained 83,656 interactions between 
11,930 proteins.  
 
Protein Complex Identification 
Our goal was to identify sets of proteins (complexes) such that each complex 
consisted of a set of proteins whose expression profiles were highly similar across 
tumor profiles and that were densely connected on the protein interaction network. 
Other formulations are possible, but we chose to focus on disjoint complexes, such 
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that each protein could only belong to a single complex. We did not require that every 
protein be assigned to a complex. 
 
There are three components to our approach 1) choosing a score to evaluate the 
similarity of the expression profiles of a set of proteins 2) the identification of a 
similar score to evaluate the connectivity of a set of proteins on an interaction 
network, and 3) the identification of sets of proteins that score well on both datasets. 
 
1) Scoring complexes using expression profiles 
We calculate the Pearson’s correlation coefficient between each pair of expression 
profiles (A, B) and use this to compute a log-likelihood ratio that A and B belong 
to the same protein complex versus the likelihood that they are unrelated. This can 
formalized as follows: 
 
LLRexpression(A, B) = Pwithin(A, B) / Pbackground(A, B) 
 
Pwithin is calculated using logistic regression trained on CORUM co-complexed pairs 
(Ruepp et al., 2010) as true positive examples. To prevent bias resulting from the 
large number of co-complex pairs falling within extraordinarily large complexes (e.g. 
Spliceosome, Proteasome, Ribosome) we exclude CORUM complexes containing 
more than 30 proteins from our training set. We assume a ratio of 300 negatives for 
every true positive, consistent with estimates of the size of the human interactome 
(Stumpf et al., 2008). Negative training examples are chosen randomly from the set of 
proteins with measured protein expression. Pbackground is the probability of observing 
the measured correlation between A and B in the set of all pairwise correlations. 
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For each set of proteins (S) we calculate the total LLRexpression(S) as the sum of all 
LLRexpression(A,B) scores for all unordered pairs (A,B) in the set S.  
 
2) Scoring complexes using the protein-protein interaction network 
For the protein-protein interaction network we sought to score each pair of proteins 
based on how likely they are to form part of the same complex. While direct protein-
protein interaction provides an indication that two proteins may be part of a protein 
complex, previous work has demonstrated that taking into account the fraction of 
interaction partners shared by two proteins can provide additional support of co-
complex membership (Bader et al., 2004; Goldberg and Roth, 2003). Based on this 
principle we assigned a weighted score to every pair of interacting proteins in our 
integrated network accounting for the proportion of interaction partners they share. 
This score was equal to a –log10 transformed p-value calculated from a 
hypergeometric test that assessed the significance of the number of interaction 
partners they shared. An advantage of this approach is that two proteins that interact 
with each other directly and share all of their interaction partners will be given a 
higher score than two proteins that interact with each other but have no other 
interaction partners in common.  
 
As with the protein expression correlation, this score was transformed into log-
likelihood ratio (LLRinteraction) by comparing the probability of observing a particular 
score within a protein complex to the probability of observing it among all pairs of 
proteins. For each set of proteins (S) we calculate the total LLRinteraction(S) as the sum 
of all LLRinteraction(A,B) scores for all unordered pairs (A,B) in the set S.  
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3) Identifying complexes supported by both data sources 
For each set of proteins we can assign a score LLRintegrated(S), which is equal to the 
sum of LLRexpression(S) and LLRinteraction(S). We found that this LLRinteraction score 
predicted co-complex membership better than co-expression alone (Figure S1E). 
Our challenge is the identification of sets of proteins with high LLRintegrated scores. As 
we are only interested in sets of proteins that score well on both resources we can 
restrict our search to those sets that have a positive LLRinteraction and a positive 
LLRexpression (i.e. we are only interested in sets of proteins that have highly correlated 
protein expression and are densely connected on the protein interaction network, not 
one or the other).  
 
We identify high-scoring sets of proteins using an approach resembling agglomerative 
hierarchical clustering. Similar approaches have been used previously to identify 
complexes supported by genetic interaction and protein interaction networks in 
budding yeast (Bandyopadhyay et al., 2008) and also to identify complexes supported 
by the genetic interaction networks of two distinct yeast species (Ryan et al., 2012).  
 
To initialize our clusters we first evaluate LLRintegrated for all pairs of proteins that 
directly interact in the protein-protein interaction network. We also evaluate scores 
for all possible 3-cliques (sets of three proteins that all interact with each other) in the 
protein-protein interaction network. The highest scoring pair or 3-clique is taken as an 
initial cluster, and all overlapping pairs or 3-cliques are then removed from 
consideration. The second highest scoring pair or 3-clique is then assigned as a 
cluster, and any overlapping pairs or 3-cliques removed from consideration. This 
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continues until no pairs or 3-cliques with positive LLRintegrated scores remain. At the 
end of the process proteins that have not been assigned to any cluster are assigned to 
their own single element cluster. We then apply an iterative approach to improve 
these clusters. At each iteration we consider three possible moves – merging, removal 
and switching. Each pair of clusters (m1,m2) is evaluated for merging into a single 
cluster (m1 U m2) and assigned a score LLRintegrated(m1,m2). For every protein in every 
cluster with multiple proteins we also calculate a LLRremove score that reflects the 
change in the log likelihood resulting from removing that protein from the cluster, and 
an LLRswitch score that calculates the change in likelihood from switching a protein 
from one cluster to another. At each iteration max(LLRmerge, LLRremove, LLRswitch) is 
taken as the next move. To prevent the identification of clusters supported by only 
one data source (e.g. highly correlated expression but not densely connected on the 
protein interaction network) we only permitted moves in cases where the move 
resulted in an increase in the LLR score for both the expression and the protein 
interaction networks. Iterations continue until no move that increases the LLR score 
on both sources is identified. The end result is a list of clusters with an associated 
LLR score.  
 
Estimating a protein complex false discovery rate  
We assume that by chance some proteins that interact on the protein interaction 
network would have high co-expression scores and consequently we could identify 
clusters with positive LLRexpression and LLRinteraction scores. To remove potentially 
spuriously detected clusters we compared the clusters we identified to those identified 
using 10 randomized versions of the input - the same protein interaction network and 
expression set, but with the gene IDs on the expression set shuffled.  These 
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randomized networks allowed us to empirically estimate the False Discovery Rate as 
we could see for a given LLRintegrated score how many genes would be assigned to 
complexes in the randomized networks compared to the genes assigned to complexes 
in the real network. We chose an FDR of 10% for defining the BrCa-Core set of 
complexes. 
 
Protein Complex Evaluation 
To assess the overlap between BrCa-Core complexes and existing annotation sets 
(CORUM complexes, Gene Ontology Cellular Compartment, Gene Ontology 
Biological Process) we used the gProfiler tool (Reimand et al., 2016). Only genes 
present in both the protein-interaction network and the tumor proteome expression 
were used as the background list or this enrichment. Multiple testing correction was 
performed using the default g:SCS approach (Reimand et al., 2016). 
 
We calculated the average Pearson correlation between complex subunits using the 
dataset of Tyanova et al (Tyanova et al., 2016) and Pozniak et al (Pozniak et al., 
2016). For this analysis we excluded pairs of proteins whose genes reside on the same 
chromosome to avoid high correlation resulting solely from co-amplification/co-
deletion events. For the shRNA data from (Marcotte et al., 2016) we calculated the 
Pearson’s correlation of co-complexed pairs using the zGARP profiles of 77 breast 
cancer cell lines. 
 
From the STRING database (Szklarczyk et al., 2017) we extracted pairs of proteins 
that are frequently mentioned together in the literature (textmining score > 250) and 
that tend to co-occur in a significant pattern across species (cooccurence score > 0). 
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Fisher’s exact test was used to assess the significance of the overlap between the 
BrCa-Core co-complexed pairs and these reference datasets. 
 
Identifying subtype specific complex expression 
To identify protein complexes differentially expressed in specific breast cancer 
subtypes we used a variant of the 1D annotation enrichment test proposed by Cox and 
Mann (Cox and Mann, 2012). For each protein we calculate the difference between 
the median expression of samples from a specific subtype and the median expression 
of samples from all other subtypes combined.  We then applied a Mann Whitney test 
to these median differences to see if the members of a given protein complex are 
among the most significantly differentially expressed proteins in a particular subtype 
(i.e. to see if all/most complex members are at one end of a ranked list of 
differentially expressed proteins). This test is performed in a two-sided fashion to 
identify complexes that are either over- or under-expressed in specific subtypes. All 
protein complexes with more than two members are tested for differential expression 
in all three subtypes. We correct for multiple-hypothesis testing using the Benjamini 
and Hochberg approach (Benjamini and Hochberg, 1995), and identified a set of 82 
differentially expressed complexes at an FDR of 10%. We then tested these 
complexes for differential expression in the dataset of Tyanova et al at the same FDR. 
As not every BrCa-Core complex is represented by multiple members in Tyanova et 
al we could test only 59 of these associations. The s-score (Cox and Mann, 2012) was 
used to measure the effect size of the association between protein complex expression 
and subtype, and Spearman’s correlation was used to assess the concordance of effect 
sizes between the associations identified in the Mertins et al data and those in 
Tyanova et al.  
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Mutation, copy number, mRNA and RPPA data 
Sequence, copy number and mRNA expression profiles for were all obtained through 
the cBioPortal (Breast Invasive Carcinoma, TCGA Provisional) (Gao et al., 2013). To 
identify associations between mutation/deletion and protein abundance we annotated 
all tumor samples according to whether or not they featured mutations or deletions in 
each of the genes coding for proteins in the BrCa-Core set. For copy number profiles 
we considered genes to be homozygously deleted in a specific sample if they had a 
GISTIC score of -2 and hemizygously deleted if they had a GISTIC score of -1. We 
considered genes to be mutated if they harbored a non-synonymous missense 
mutation, splice-site mutation, an insertion or deletion, or a nonsense mutation. For 
the RPPA analysis and mRNA expression analysis presented in Figure 4 we used the 
Z-score normalized expression levels available through the cBioPortal (Gao et al., 
2013). 
 
Associating mutation / deletion with complex expression 
To assess how genetic variants altered the overall abundance of protein complexes to 
which they were associated, we first converted the quantitative measurements of 
protein expression into rank orders. In each sample we then calculated the mean rank 
of all complex members, and tested if samples harboring the alteration of interest 
displayed lower mean rank than samples without the alteration using a one-sided 
Mann Whitney U test. The mean rank was calculated with the deleted gene excluded 
(e.g. COPS3 was excluded when calculating the mean rank of the COP9 signalsome). 
For deletions (homozygous or hemizygous) complex members on the same 
chromosome as the altered gene were also excluded from the mean rank calculation. 
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MCF7 proteomic analysis  
Mass spectra were analyzed using MaxQuant software (version 1.5.0.25)(Cox and 
Mann, 2008)  containing the in-built Andromeda search engine to identify the proteins 
from a human database (Uniprot HUMAN, release 2012_01) containing 20,242 
entries. Default parameters were selected in MaxQuant with the exception of the 
selection of the relevant enzyme, (LysC and Trypsin digests were separated between 
parameter groups). For database searches, the precursor mass tolerance was set to 20 
ppm for first searches and 4.5 ppm for main Andromeda search. The search included 
a fixed modification of Carbamidomethyl (C) and variable modifications of Oxidation 
(M);Acetyl (Protein N-term). Label free quantification with a minimum ratio count of 
2 was selected, the maximum number of missed cleavages was set at 2 and minimum 
peptide length was set to 7 amino acids. An FDR of 0.01 was set for peptide and 
protein identifications. Match between runs was selected with a matching time 
window of 0.7 min and alignment time window of 20min. The presence of reverse 
and contaminant identifications were removed from the dataset.  
 
Differential expression analysis 
Proteomic profiles were generated for three biological replicates of the parental 
(CDH1 wild-type) and CDH1-defective cell lines. Two technical replicates were 
obtained for each biological replicate and these were averaged prior to further 
analysis. Missing values were imputed using the minimum observed intensity for each 
sample, based on the assumption that missing proteins could be absent or below the 
detection threshold of the instrument. Log2 transformed LFQ (Label Free 
Quantification) values were used for analysis. A two-sided heteroscedastic t-test  
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(Welch’s t-test) was used to identify differentially expressed proteins and the 
Benjamini-Hochberg approach was used to estimate the False Discovery Rate 
(Benjamini and Hochberg, 1995).  
 
DATA AND SOFTWARE AVAILABILITY  
The MCF7 CDH+/- mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE partner repository with the dataset 
identifier PXD007543. Python code for the complex identification method, along with 
necessary input data, can be obtained from: https://github.com/cancergenetics/brca-
core 
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Supplemental Table Legends 
Table S1. BrCa-Core complex composition (Related to Figure 1) 
Table S2. Subtype specific BrCA-Core complex expression (Related to Figure 2) 
Table S3. Collateral loss events associated with hemizygous deletion (Related to 
Figure 3) 
Table S4. MCF7 CDH1 isogenic protein expression profiles (Related to Figure 4) 
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